Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments Corp experienced a significant 53% year-over-year growth in Medicare Advantage membership, which is pivotal as this segment accounts for approximately 97% of its total membership. The adoption of Clover Assistant is expected to enhance medical cost ratios, thereby improving unit economics and contribution margin as new members join in 2026. Additionally, the company anticipates financial benefits from its 4-star plan rating and favorable CMS rate updates, projecting an increase in new member revenue that exceeds $70 per member per month, further solidifying a positive financial outlook.

Bears say

Clover Health Investments Corp exhibits several concerns that contribute to a negative outlook on its stock performance. Despite a maintained adjusted EBITDA of $22.6 million amid a 33% increase in average Medicare Advantage (MA) membership, the company faces potential challenges in maintaining its 4-Star rating, which could adversely affect future medical loss ratio (MLR) and earnings metrics. Additionally, the upcoming 2026 guidance signals a decrease in gross profit margins due to dilution from new members and is further clouded by regulatory changes and heightened competition in the Medicare Advantage market.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of Apr 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.